1,1-and 1,2-Bisphosphonates as apoliprotein e modulators
申请人:Montes Flores Imber
公开号:US20060205692A1
公开(公告)日:2006-09-14
The present invention relates to methods of use 1,1- and 1,2-bisphosphonate compounds to modulate apolipoprotein E levels and use of such compounds in therapy, including cardiovascular and neurological disease states.
Calix[4]arene methylenebisphosphonic acids as calf intestine alkaline phosphatase inhibitors
作者:Andriy I. Vovk、Vitaly I. Kalchenko、Sergey A. Cherenok、Valery P. Kukhar、Oxana V. Muzychka、Myron O. Lozynsky
DOI:10.1039/b409526j
日期:——
Calix[4]arenes bearing one or two methylenebisphosphonic acid fragments were prepared via addition of diethylphosphite to the parent calix[4]arene aldehydes. The resulting compounds displayed stronger inhibition of calf intestine alkaline phosphatase than simple methylenebisphosphonic or 4-hydroxyphenyl methylenebisphosphonic acids. The action of these phosphorylated calix[4]arenes is concordant with partial mixed-type inhibition. The inhibition constants Ki and Ki′ for the calix[4]arene bis(methylenebisphosphonic) acid in Tris-HCl buffer at pH 9 are 0.38 µM and 2.8 µM respectively. The replacement of the phosphoric acid moieties on the macrocycle with diethylphosphonates results in a sharp decrease of its inhibitory action. Preorganizing phosphonic acid fragments using a calixarene platform therefore provides a promising approach for the design of efficient alkaline phosphatase inhibitors.